In ₹ Crore except Per Share Latest Annual	SHILPAMED FY26	NATCOPHARM FY26	SPARC FY26	STAR FY26	Peer Average
Valuation — at last close
P/E	75.21×	9.94×	◆ 3.82×	18.19×	10.65× +606%
P/B	7.06×	◆ 1.53×	4.43×	3.26×	3.07× +130%
EV/EBITDA	43.51×	8.82×	◆ 4.06×	12.55×	8.48× +413%
Market Cap	₹18,300 Cr	₹14,097 Cr	₹5,938 Cr	₹10,116 Cr	₹10,050 Cr +82%
Growth
Revenue CAGR 3Y	13.59%	14.64%	◆ 95.98%	9.62%	40.08% -66%
Revenue CAGR 5Y	11.30%	◆ 14.72%	—	7.94%	11.33% 0%
Net Income CAGR 3Y	—	25.64%	—	—	25.64%
Revenue YoY (latest Q)	44.90%	-44.68%	◆ 314.11%	17.11%	95.51% -53%
Net Income YoY (latest Q)	◆ 115.16%	-57.01%	59.94%	1.97%	1.63% +6951%
Profitability
EBITDA Margin	28.25%	35.22%	◆ 85.08%	19.04%	46.45% -39%
Net Income Margin	15.81%	34.78%	◆ 82.65%	11.82%	43.08% -63%
Return on Common Equity	9.80%	16.86%	◆ 277.35%	19.66%	104.62% -91%
Return on Capital Employed	11.47%	14.40%	◆ 230.55%	19.31%	88.09% -87%
Return on Assets	6.94%	14.40%	◆ 123.94%	8.86%	49.07% -86%
Credit & Quality
Total Debt/Equity	0.25×	◆ 0.08×	0.42×	0.53×	0.34× -27%
Interest Coverage	5.36×	33.51×	◆ 46.54×	4.05×	28.03× -81%
Scale — latest FY
Revenue / Total Income	₹1,539 Cr	₹4,078 Cr	₹1,879 Cr	₹4,859 Cr	₹3,605 Cr -57%
Net Income	₹243 Cr	₹1,419 Cr	₹1,553 Cr	₹575 Cr	₹1,182 Cr -79%
Total Assets	₹3,706 Cr	₹11,074 Cr	₹2,171 Cr	₹6,927 Cr	₹6,724 Cr -45%
EPS	₹12.44	₹79.2	₹47.86	₹60.34	₹62.47 -80%
Book Value per Share	₹132.47	₹515.15	₹41.26	₹337.14	₹297.85 -56%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.